Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.

The efficacy and limitations of presently available therapies for pulmonary hypertension that target NO signaling are reviewed along with an update on investigational therapies that use this pathway to reverse pulmonary hypertensive changes.